NEW YORK (GenomeWeb) – Agilent Technologies' Dako business said today that it will develop a companion diagnostic test for a cancer drug being developed by Merck.
The test will be for the analysis of the potential tumor biomarker PD-L1 as an aid in treating cancer patients with Merck's investigational anti-PD-1 antibody. Financial and other terms of the agreement were not disclosed.
Eric Rubin, VP of oncology for Merck Research Laboratories, said that early findings from its clinical development program have "provided evidence for the potential of PD-L1 tumor expression to aid study enrichment and patient selection in some tumor types."
Neither company specified the particular cancers Merck will target with its drug.